Related Experiment Video
Updated: Dec 22, 2025

Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade
Published on: August 14, 2019
Research Progress in Flavonoids as Potential Anticancer Drug Including Synergy with Other Approaches
Yusuf Hussain1, Suaib Luqman1, Abha Meena1
1Molecular Bioprospection Department of Biotechnology Division, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow-226015, Uttar Pradesh, India.
Background:
In chemotherapy for cancer, conventional drugs aim to target the rapidly growing and dividing cells at the early stages. However, at an advanced stage, cancer cells become less susceptible because of the multidrug resistance and the recruitment of alternative salvage pathways for their survival. Besides, owing to target non-selectivity, healthy proliferating cells also become vulnerable to the damage. The combination therapies offered using flavonoids to cure cancer not only exert an additive effect against cancer cells by targetting supplementary cell carnage pathways but also hampers the drug resistance mechanisms. Thus, the review aims to discuss the potential and pharmacokinetic limitations of flavonoids in cancer treatment. Further successful synergistic studies reported using flavonoids to treat cancer has been described along with potential drug delivery systems.
Methods:
A literature search was done by exploring various online databases like Pubmed, Scopus, and Google Scholar with the specific keywords like "Anticancer drugs", "flavonoids", "oncology research", and "pharmacokinetics".
Results:
Dietary phytochemicals, mainly flavonoids, hinder cell signalling responsible for multidrug resistance and cancer progression, primarily targeting cancer cells sparing normal cells. Such properties establish flavonoids as a potential candidate for synergistic therapy. However, due to low absorption and high metabolism rates, the bioavailability of flavonoids becomes a challenge. Such challenges may be overcome using novel approaches like derivatization, and single or co-delivery nano-complexes of flavonoids with conventional drugs. These new approaches may improve the pharmacokinetic and pharmacodynamic of flavonoids.
Conclusion:
This review highlights the application of flavonoids as a potential anticancer phytochemical class in combination with known anti-cancer drugs/nanoparticles. It also discusses flavonoid's pharmacokinetics and pharmacodynamics issues and ways to overcome such issues. Moreover, it covers successful methodologies employed to establish flavonoids as a safe and effective phytochemical class for cancer treatment.
Insights
Flavonoids show promise in combination cancer therapy by targeting cancer cells and overcoming drug resistance. However, their bioavailability challenges can be addressed with advanced delivery systems for improved efficacy.
Area of Science:
- Phytochemistry and Pharmacology
- Oncology Research
- Drug Delivery Systems
Background:
- Conventional chemotherapy faces challenges in advanced cancer due to multidrug resistance and off-target effects on healthy cells.
- Flavonoids offer a synergistic approach, targeting supplementary cancer cell death pathways and overcoming resistance mechanisms.
- This review explores the potential and limitations of flavonoids in cancer treatment.
Purpose of the Study:
- To discuss the potential of flavonoids as anticancer agents in combination therapies.
- To review the pharmacokinetic limitations of flavonoids and strategies to overcome them.
- To highlight successful synergistic studies and novel drug delivery systems for flavonoids in oncology.
Main Methods:
- A comprehensive literature search was conducted using databases such as PubMed, Scopus, and Google Scholar.
- Keywords included "Anticancer drugs", "flavonoids", "oncology research", and "pharmacokinetics" to identify relevant studies.
Main Results:
- Flavonoids, as dietary phytochemicals, inhibit cell signaling pathways involved in multidrug resistance and cancer progression, sparing normal cells.
- Their potential for synergistic therapy is established, but low absorption and high metabolism limit bioavailability.
- Novel approaches like derivatization and nano-complexes show promise in enhancing flavonoid pharmacokinetics and pharmacodynamics.
Conclusions:
- Flavonoids represent a promising phytochemical class for combination anticancer therapy with conventional drugs or nanoparticles.
- Addressing pharmacokinetic and pharmacodynamic challenges through innovative delivery systems is crucial for their clinical application.
- Methodologies for establishing flavonoids as safe and effective anticancer agents are discussed, paving the way for their use in cancer treatment.
More Related Videos
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
Cancer Prevention
Some...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inhibition of Cdk Activity
Combined Effects of Drugs: Synergism
Such synergistic combinations...